Edith Zemanick, MD

Professional Titles

• Clinical Research Medical Director, Breathing Institute
• Associate Director, Pediatric Cystic Fibrosis Center, Children's Hosptial Colorado
• Pediatric Pulmonary Fellowship Research Director

Recognitions

• Outstanding Master of Science in Clinical Sciences Student Award, University of Colorado Denver (2006)
  
• The Maynard Cohen Award in Pediatrics, Children's National Medical Center, George Washington University (2002)
  
• Alpha Omega Alpha Honor Society, Albert Einstein College of Medicine, Yeshiva University (1998)
  
• The American Medical Women's Association, Janet M. Glasgow Achievement Citation, Albert Einstein College of Medicine, Yeshiva University (2002)
  
• CU Anschutz Graduate School Dean's Master's Mentoring Award, University of Colorado (2021)
• Professional Leadership Award, Women in Medicine and Science Office, University of Colorado School of Medicine (2014)

Research Interests

Cystic fibrosis, clinical trials, infection

Publications

• Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2012 Nov 1;186(9):857-65. PubMed PMID: 22904182
• Wagener JS, Zemanick ET, Sontag MK. Newborn screening for cystic fibrosis. Curr Opin Pediatr. 2012 Jun;24(3):329-35. PubMed PMID: 22491493
• Zemanick, ET and Harris, JK. The Human Airway Microbiome. In, DN Fredricks, editor. The Human Microbiota: How Microbial Communities Affect Health and Disease. 2013
• Federico MJ, Stillwell P, Deterding RR, Baker CD., Balasubramaniam V, Zemanick ET, Sagel SD, Halbower A, Burg CJ and Kerby GS. Respiratory tract and mediastinum. In: Hay WW, Levin MJ, Deterding RR, Abzug MJ, and Sondheimer JM, editors. Current Diagnosis and Treatment: Pediatrics, Twenty-First Edition. McGraw-Hill Companies, New York, NY, 2012.
• Zemanick ET, Hoffman L, Rosenfeld M. Narrowing in on early cystic fibrosis lung disease. Am J Respir Crit Care Med. 2014 Nov 15;190(10):1082-4. PubMed PMID: 25398104
• Martiniano SL, Hoppe JE, Sagel SD, Zemanick ET. Advances in the diagnosis and treatment of cystic fibrosis. Adv Pediatr. 2014 Aug;61(1):225-43. PubMed PMID: 25037130
• Zemanick ET, Accurso FJ. Cystic fibrosis transmembrane conductance regulator and pseudomonas. Am J Respir Crit Care Med. 2014 Apr 1;189(7):763-5. PubMed PMID: 24684355
• Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M, EPIC Study Group. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol. 2015 Jan;50(1):42-8. PubMed PMID: 24644274
• Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax. 2016 Nov 15. [Epub ahead of print] PubMed PMID: 27852955
• Zemanick ET, Hoffman LR. Cystic Fibrosis: Microbiology and Host Response. Pediatr Clin North Am. 2016 Aug;63(4):617-36. PubMed PMID: 27469179
• Zemanick ET, Ong T, Daines CL, Dellon EP, Muhlebach MS, Esther CR Jr. Highlights from the 2015 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2016 Jun;51(6):650-7. PubMed PMID: 27074261
• Martiniano SL, Sagel SD, Zemanick ET. Cystic fibrosis: a model system for precision medicine. Curr Opin Pediatr. 2016 Jun;28(3):312-7. PubMed PMID: 27031658
• Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Guill MF, Guillerman RP, Leone CG, Maguiness K, Monchil L, Powers SW, Rosenfeld M, Schwarzenberg SJ, Tompkins CL, Zemanick ET, Davis SD. Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics. 2016 Apr;137(4). PubMed PMID: 27009033
• Zemanick ET, Wainwright C. Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects. Am J Respir Crit Care Med. 2016 Mar 1;193(5):473-4. PubMed PMID: 26930426
• Johnson EJ, Zemanick ET, Accurso FJ, Wagner BD, Robertson CE, Harris JK. Molecular Identification of Staphylococcus aureus in Airway Samples from Children with Cystic Fibrosis. PLoS One. 2016 Jan 25;11(1):e0147643. PubMed PMID: 26808658
• Zemanick ET, Laguna TA. Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?. Clin Infect Dis. 2015 Sep 1;61(5):716-8. PubMed PMID: 25972023
• Ma DC, Yoon AJ, Faull KF, Desharnais R, Zemanick ET, Porter E. Cholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients. PLoS One. 2015 Apr 28;10(4):e0125326. PubMed PMID: 25919295
• Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, Sokol RJ, Zemanick E, Accurso F, Hoffenberg EJ, Narkewicz MR. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One. 2015 Feb 6;10(2):e0116967. PubMed PMID: 25658710
• Hoppe JE, Towler E, Wagner BD, Accurso FJ, Sagel SD, Zemanick ET. Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatr Pulmonol. 2015 Jul;50(7):638-46. PubMed PMID: 25565628
• Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, Szefler SJ, Accurso FJ, Sagel SD, Harris JK. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc. 2015 Feb;12(2):221-9. PubMed PMID: 25474078
• Laguna TA, Wagner BD, Williams CB, Stevens MJ, Robertson CE, Welchlin CW, Moen CE, Zemanick ET, Harris JK. Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis. PLoS One. 2016 Dec 8;11(12):e0167649. PubMed PMID: 27930727
• Harris JK, Zemanick ET. Microbes in bronchiectasis: the forest or the trees?. Am J Respir Crit Care Med. 2013 May 15;187(10):1044-5. PubMed PMID: 23675713
• Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One. 2013;8(4):e62917. PubMed PMID: 23646159
• Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J. 2017 Nov;50(5). PubMed PMID: 29146601
• Zemanick ET, Daines CL, Dellon EP, Esther CR Jr, Kinghorn B, Ong T, Muhlebach MS. Highlights from the 2016 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2017 Aug;52(8):1103-1110. PubMed PMID: 28696526
• Hoppe JE, Wagner BD, Sagel SD, Accurso FJ, Zemanick ET. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulm Med. 2017 Dec 11;17(1):188. PubMed PMID: 29228933
• Williamson KM, Wagner BD, Robertson CE, Johnson EJ, Zemanick ET, Harris JK. Impact of enzymatic digestion on bacterial community composition in CF airway samples. PeerJ. 2017;5:e3362. PubMed PMID: 28584706
• Hoppe JE, Zemanick ET. Lessons from the lower airway microbiome in early CF. Thorax. 2017 Dec;72(12):1063-1064. PubMed PMID: 28450530
• Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May;16(3):371-379. PubMed PMID: 28209466
• Li A, Vigers T, Pyle L, Zemanick E, Nadeau K, Sagel SD, Chan CL. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. J Cyst Fibros. 2018 Aug 10. [Epub ahead of print] PubMed PMID: 30104123
• Wagner BD, Grunwald GK, Zerbe GO, Mikulich-Gilbertson SK, Robertson CE, Zemanick ET, Harris JK. On the Use of Diversity Measures in Longitudinal Sequencing Studies of Microbial Communities. Front Microbiol. 2018;9:1037. PubMed PMID: 29872428
• Martiniano SL, Toprak D, Ong T, Zemanick ET, Daines CL, Muhlebach MS, Esther CR Jr, Dellon EP. Highlights from the 2017 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2018 Jul;53(7):979-986. PubMed PMID: 29660839
• Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA. Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2019 Oct 31. [Epub ahead of print] PubMed PMID: 31680041
• Nasir M, Bean HD, Smolinska A, Rees CA, Zemanick ET, Hill JE. Volatile molecules from bronchoalveolar lavage fluid can 'rule-in' Pseudomonas aeruginosa and 'rule-out' Staphylococcus aureus infections in cystic fibrosis patients. Sci Rep. 2018 Jan 16;8(1):826. PubMed PMID: 29339749
• Juarez-Colunga E, Rosenfeld M, Zemanick ET, Wagner B. Analysis of recurrent pulmonary exacerbations in Cystic Fibrosis Children: EPIC Observational Study, Journal of Cystic Fibrosis, 2018, in press.
• Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, Rowe SM, Sagel SD. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Ann Am Thorac Soc. 2019 Oct 11. [Epub ahead of print] PubMed PMID: 31604026
• Jewell MP, Galyean AA, Kirk Harris J, Zemanick ET, Cash KJ. Luminescent Nanosensors for Ratiometric Monitoring of Three-Dimensional Oxygen Gradients in Laboratory and Clinical Pseudomonas aeruginosa Biofilms. Appl Environ Microbiol. 2019 Oct 15;85(20). PubMed PMID: 31420335
• Theprungsirikul J, Skopelja-Gardner S, Meagher RE, Clancy JP, Zemanick ET, Ashare A, Rigby WFC. Dissociation of systemic and mucosal autoimmunity in cystic fibrosis. J Cyst Fibros. 2019 Jun 28. [Epub ahead of print] PubMed PMID: 31262645
• Martiniano SL, Daines CL, Dellon EP, Esther CR Jr, Muhlebach MS, Ong T, Rabinowitz EC, Toprak D, Zemanick ET. Highlights from the 2018 North American cystic fibrosis conference. Pediatr Pulmonol. 2019 Jul;54(7):941-948. PubMed PMID: 31091021
• Hahn A, Fanous H, Jensen C, Chaney H, Sami I, Perez GF, Koumbourlis AC, Louie S, Bost JE, van den Anker JN, Freishtat RJ, Zemanick ET, Crandall KA. Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis. Sci Rep. 2019 Feb 22;9(1):2534. PubMed PMID: 30796252
• Hoppe JE, Wagner BD, Accurso FJ, Zemanick ET, Sagel SD. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. 2018 Nov;17(6):760-768. PubMed PMID: 29921503
• Hahn A and Zemanick ET. Bacterial Community Variability: Outliers May Be Leading Us Astray. Annals ATS 2019;16(12):1499–1501.
• Martiniano SL, Esther CR, Haworth CS, Kasperbauer SH, Zemanick ET, Caverly LJ. Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis. Pediatr Pulmonol. 2019 Dec 10. [Epub ahead of print] PubMed PMID: 31821718
• Hahn A, Zemanick ET. Bacterial Community Variability: Outliers May Be Leading Us Astray. Ann Am Thorac Soc. 2019 Dec;16(12):1499-1501. PubMed PMID: 31774321
• Hoppe JE, Hinds DM, Colborg A, Wagner BD, Morgan WJ, Rosenfeld M, Zemanick ET, Sanders DB. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatr Pulmonol. 2020 Dec;55(12):3400-3406. PubMed PMID: 32970375
• Hahn A, Burrell A, Ansusinha E, Peng D, Chaney H, Sami I, Perez GF, Koumbourlis AC, McCarter R, Freishtat RJ, Crandall KA, Zemanick ET. Airway microbial diversity is decreased in young children with cystic fibrosis compared to healthy controls but improved with CFTR modulation. Heliyon. 2020 Jun;6(6):e04104. PubMed PMID: 32514485
• Poore TS, Meier M, Towler E, Martiniano SL, Brinton JT, DeBoer EM, Sagel SD, Wagner BD, Zemanick ET. Clinical characteristics of people with cystic fibrosis and frequent fungal infection. Pediatr Pulmonol. 2021 Oct 23. [Epub ahead of print] PubMed PMID: 34687280
• Zemanick ET, Accurso FJ. Entering the era of highly effective CFTR modulator therapy. Lancet. 2019 Nov 23;394(10212):1886-1888. PubMed PMID: 31679947
• Bozzella MJ, Chaney H, Sami I, Koumbourlis A, Bost JE, Zemanick ET, Freishtat RJ, Crandall KA, Hahn A. Impact of Anaerobic Antibacterial Spectrum on Cystic Fibrosis Airway Microbiome Diversity and Pulmonary Function. Pediatr Infect Dis J. 2021 Nov 1;40(11):962-968. PubMed PMID: 34269323
• Poore TS, Hong G, Zemanick ET. Fungal Infection and Inflammation in Cystic Fibrosis. Pathogens. 2021 May 18;10(5). PubMed PMID: 34069863
• Zemanick ET, Bell SC. Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis. Curr Opin Pulm Med. 2019 Nov;25(6):636-645. PubMed PMID: 31397692
• Zemanick ET, Polineni D. Unraveling the CFTR Function-Phenotype Connection for Precision Treatment in Cystic Fibrosis. Am J Respir Crit Care Med. 2019 May 1;199(9):1053-1054. PubMed PMID: 30939246
• DeBoer EM, Wagner BD, Popler J, Harris JK, Zemanick ET, Accurso FJ, Sagel SD, Deterding RR. Novel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid. Proteomics Clin Appl. 2019 May;13(3):e1800085. PubMed PMID: 30431231
• Hahn A, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Zemanick ET, Louie S, Crandall KA. Importance of beta-lactam pharmacokinetics and pharmacodynamics on the recovery of microbial diversity in the airway of persons with cystic fibrosis. J Investig Med. 2021 Oct;69(7):1350-1359. PubMed PMID: 34021052
• Drake MG, Shah NG, Lee M, Brady A, Connors GR, Clark BJ, Kritek PA, McCallister JW, Burkart KM, Pedraza I, Jamieson D, Ingram JL, Lynch L, Makani SS, Siegel-Gasiewski J, Larsson EM, Zemanick ET, Liptzin DR, Good R, Crotty Alexander LE. Development of a National Academic Boot Camp to Improve Fellowship Readiness. ATS Sch. 2020 Dec 22;2(1):49-65. PubMed PMID: 33870323
• Lenhart-Pendergrass PM, Anthony M, Sariyska S, Andrews A, Scavezze H, Towler E, Martiniano SL, Hoppe JE, Zemanick ET. Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis. Pediatr Pulmonol. 2021 Jul;56(7):2043-2047. PubMed PMID: 33847465
• Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1522-1532. PubMed PMID: 33734030
• Wagner BD, Berkalieva A, Borges M, Fleming G, Graham N, Peterson E, Jin X, Zemanick ET. Change in circulating proteins during treatment of pulmonary exacerbation in patients with cystic fibrosis. Health Sci Rep. 2021 Mar;4(1):e246. PubMed PMID: 33614983
• Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J Cyst Fibros. 2021 Feb 8. [Epub ahead of print] PubMed PMID: 33573995
• Khalaf RT, Furuta GT, Wagner BD, Robertson CE, Andrews R, Stevens MJ, Fillon SA, Zemanick ET, Harris JK. Influence of Acid Blockade on the Aerodigestive Tract Microbiome in Children With Cystic Fibrosis. J Pediatr Gastroenterol Nutr. 2021 Apr 1;72(4):520-527. PubMed PMID: 33394582
• Jewell MP, Saccomano SC, David AA, Harris JK, Zemanick ET, Cash KJ. Nanodiagnostics to monitor biofilm oxygen metabolism for antibiotic susceptibility testing. Analyst. 2020 Jun 7;145(11):3996-4003. PubMed PMID: 32342070
• Juarez-Colunga E, Rosenfeld M, Zemanick ET, Wagner B. Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. J Cyst Fibros. 2020 Jan;19(1):114-118. PubMed PMID: 30642785
• Inam Z, Felton E, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Zemanick ET, Crandall KA, Hahn A. Impact of Antibiotics on the Lung Microbiome and Lung Function in Children With Cystic Fibrosis 1 Year After Hospitalization for an Initial Pulmonary Exacerbation. Open Forum Infect Dis. 2022 Sep;9(9):ofac466. PubMed PMID: 36168550
• Hoppe JE, Zemanick ET, Martiniano SL. Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing. Am J Respir Crit Care Med. 2022 Dec 1;206(11):1308-1310. PubMed PMID: 35947636
• Mayer-Hamblett N, Zemanick ET, Odem-Davis K, VanDevanter D, Warden M, Rowe SM, Young J, Konstan MW, For-The-Chec-Sc-Study-Group. Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study. J Cyst Fibros. 2022 Jul 21. [Epub ahead of print] PubMed PMID: 35871974
• Rice JD, Johnson RL, Juarez-Colunga E, Zemanick ET, Rosenfeld M, Wagner BD. Application of gap time analysis with flexible hazards to pulmonary exacerbations in the EPIC observational study. Biom J. 2022 Aug;64(6):1075-1089. PubMed PMID: 35434808
• Broderick DTJ, Waite DW, Marsh RL, Camargo CA Jr, Cardenas P, Chang AB, Cookson WOC, Cuthbertson L, Dai W, Everard ML, Gervaix A, Harris JK, Hasegawa K, Hoffman LR, Hong SJ, Josset L, Kelly MS, Kim BS, Kong Y, Li SC, Mansbach JM, Mejias A, O'Toole GA, Paalanen L, Pérez-Losada M, Pettigrew MM, Pichon M, Ramilo O, Ruokolainen L, Sakwinska O, Seed PC, van der Gast CJ, Wagner BD, Yi H, Zemanick ET, Zheng Y, Pillarisetti N, Taylor MW. Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis. Front Microbiol. 2021;12:711134. PubMed PMID: 35002989
• Poore TS, Taylor-Cousar JL, Zemanick ET. Cardiovascular complications in cystic fibrosis: A review of the literature. J Cyst Fibros. 2022 Jan;21(1):18-25. PubMed PMID: 34140249
• Jordan KD, Zemanick ET, Taylor-Cousar JL, Hoppe JE. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy. Expert Rev Respir Med. 2023 Feb;17(2):97-108. PubMed PMID: 36803356
• Miller JE, Liu CM, Zemanick ET, Woods JC, Goss CH, Taylor-Cousar JL, Beswick DM. Olfactory loss in people with cystic fibrosis: Community perceptions and impact. J Cyst Fibros. 2023 Nov 17. [Epub ahead of print] PubMed PMID: 37981480
• Wagner BD, Zemanick ET, Sagel SD, Robertson CE, Stevens MJ, Mayer-Hamblett N, Retsch-Bogart G, Ramsey BW, Harris JK. Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection. BMC Microbiol. 2023 Oct 27;23(1):312. PubMed PMID: 37891457
• Mayer-Hamblett N, Clancy JP, Jain R, Donaldson SH, Fajac I, Goss CH, Polineni D, Ratjen F, Quon BS, Zemanick ET, Bell SC, Davies JC, Jain M, Konstan MW, Kerper NR, LaRosa T, Mall MA, McKone E, Pearson K, Pilewski JM, Quittell L, Rayment JH, Rowe SM, Taylor-Cousar JL, Retsch-Bogart G, Downey DG. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. Lancet Respir Med. 2023 Oct;11(10):932-944. PubMed PMID: 37699421
• Sanders DB, Bartz TM, Zemanick ET, Hoppe JE, Hinckley Stukovsky KD, Cogen JD, Bendy L, McNamara S, Enright E, Kime NA, Kronmal RA, Edwards TC, Morgan WJ, Rosenfeld M. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Ann Am Thorac Soc. 2023 Dec;20(12):1769-1776. PubMed PMID: 37683122
• Poore TS, Zemanick ET. Infection, Allergy, and Inflammation: The Role of Aspergillus fumigatus in Cystic Fibrosis. Microorganisms. 2023 Aug 5;11(8). PubMed PMID: 37630573
• Harris JK, Wagner BD, Robertson CE, Stevens MJ, Lingard C, Borowitz D, Leung DH, Heltshe SL, Ramsey BW, Zemanick ET. Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screen. J Cyst Fibros. 2023 Jul;22(4):644-651. PubMed PMID: 37137746
• VanDevanter DR, Zemanick ET, Konstan MW, Ren CL, Odem-Davis K, Emerman I, Young J, Mayer-Hamblett N. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials. J Cyst Fibros. 2023 Jul;22(4):652-655. PubMed PMID: 37100705
• Gifford AH, Hinton AC, Jia S, Nasr SZ, Mermis JD, Lahiri T, Zemanick ET, Teneback CC, Flume PA, DiMango EA, Sadeghi H, Polineni D, Dezube RH, West NE, Dasenbrook EC, Lucas FL, Zuckerman JB. Complications and Practice Variation in the Use of Peripherally Inserted Central Venous Catheters in People With Cystic Fibrosis: The Prospective Study of Peripherally Inserted Venous Catheters in People With Cystic Fibrosis Study. Chest. 2023 Sep;164(3):614-624. PubMed PMID: 37019356
• Jordan KD, Zemanick ET, Taylor-Cousar JL, Hoppe JE. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy. Expert Rev Respir Med. 2023 Feb;17(2):97-108. PubMed PMID: 36803356
• Shumyatsky G, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Crandall KA, Zemanick ET, Hahn A. Using metabolic potential within the airway microbiome as predictors of clinical state in persons with cystic fibrosis. Front Med (Lausanne). 2022;9:1082125. PubMed PMID: 36698799
• Hahn A, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Crandall KA, Zemanick ET. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis. Sci Rep. 2023 Jan 21;13(1):1217. PubMed PMID: 36681756
• Mayer-Hamblett N, Zemanick ET, Odem-Davis K, VanDevanter D, Warden M, Rowe SM, Young J, Konstan MW, For-The-Chec-Sc-Study-Group. Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study. J Cyst Fibros. 2023 Jan;22(1):79-88. PubMed PMID: 35871974
• Metcalf A, Martiniano SL, Sagel SD, Zaretsky MV, Zemanick ET, Hoppe JE. Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. J Cyst Fibros. 2024 Dec 6. [Epub ahead of print] PubMed PMID: 39645477
• Zemanick ET, Rosas-Salazar C. The Role of the Microbiome in Pediatric Respiratory Diseases. Clin Chest Med. 2024 Sep;45(3):587-597. PubMed PMID: 39069323
• Hoppe JE, Sjoberg J, Hong G, Poch K, Zemanick ET, Thee S, Edmondson C, Patel D, Sathe M, Borowitz D, Putman MS, Lechtzin N, Riekert KA, Basile M, Goss CH, Jarosz ME, Rosenfeld M. Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force. J Cyst Fibros. 2024 Jul;23(4):725-733. PubMed PMID: 38429150
• Zemanick ET, Emerman I, McCreary M, Mayer-Hamblett N, Warden MN, Odem-Davis K, VanDevanter DR, Ren CL, Young J, Konstan MW. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. J Cyst Fibros. 2024 Jul;23(4):676-684. PubMed PMID: 38360461
• Graham BIM, Harris JK, Zemanick ET, Wagner BD. Integrating airway microbiome and blood proteomics data to identify multi-omic networks associated with response to pulmonary infection. Microbe. 2023 Dec;1. PubMed PMID: 38264413
• Miller JE, Liu CM, Zemanick ET, Woods JC, Goss CH, Taylor-Cousar JL, Beswick DM. Olfactory loss in people with cystic fibrosis: Community perceptions and impact. J Cyst Fibros. 2024 Nov;23(6):1195-1198. PubMed PMID: 37981480

Professional Memberships

• American Thoracic Society (ATS), Member
• American Academy of Pediatrics (AAP), FAAP
• Society for Pediatric Research, Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Children’s Colorado Outpatient Care at Briargate
4125 Briargate Pkwy
Colorado Springs, CO 80920
719-305-9000

Hospital Affiliation

• Children's Hospital Colorado
• University of Colorado Hospital

Specialty Information

Specialties

• Pediatric Pulmonology, Board Certification (2008)

Conditions & Treatments

• Lungs and Breathing - Pulmonary Disorders
• Child and Teen Health
• Lungs and Breathing - Cystic Fibrosis
• Lungs and Breathing - Lung Disease
• Lungs and Breathing